KRAS and neoplasm: A total of 135 plasma samples from patients with CRC, whose tissue harbored the KRAS G12D/V or G13D mutation, were tested with the ultra-high sensitivity (UHS) method and we could detect tumor-specific KRAS mutations in additional 26 plasma samples in which tumor-specific KRAS mutations had not been detected in multiplex iPLEX analysis.